A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.

Hanna K Sanoff Allision M DealJai PatelJonathan D Sorah Jacquelyne GaddyBert O'NeilAnita A TurkWilliam IrvinJeremiah BolesMichael S LeeAutumn McReeAlexis C WardellKaren E Weck Ethan M BaschWilliam A WoodFederico Innocenti

Published in: The oncologist (2024)

A pharmacogenomic-directed irinotecan strategy improved PFS in the *1/*1 and *1/*28 genotypes with higher rates of neutropenia and similar rates of diarrhea compared to expected with standard FOLFIRI dosing. However, improvements in response rate and PFS were modest. This strategy should not change standard practice for mCRC patients in the first-line setting.

Keyphrases

metastatic colorectal cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
primary care
healthcare
prognostic factors
clinical trial
open label
radiation therapy
locally advanced
study protocol
clostridium difficile
irritable bowel syndrome